Key result
Elevated sVCAM-1 concentration (≥ 1242 ng/ml) was associated with a significantly increased risk of all-cause mortality (OR 5.39) during a one-year follow-up.
Why the study?
Disturbances in atrial microcirculation are recognized as a risk factor for AF, but the associations between circulating sVCAM-1, AF risk, and one-year prognosis were undetermined.
Does elevated sVCAM-1 predict the risk of AF and adverse outcomes in inpatients with non-valvular AF?
Cohort (n=160)
No
Does elevated sVCAM-1 predict the risk of AF and adverse outcomes in inpatients with non-valvular AF?
Odds Ratio: 5.39 (95% CI 1.57–18.45)
p-value: p=0.007
Elevated sVCAM-1 is associated with increased one-year all-cause mortality and MACE in inpatients, but does not differentiate patients with non-valvular AF from those with chronic coronary syndrome.
Elevated sVCAM-1 was associated with higher one-year mortality; hypothesis-generating for risk stratification in non-valvular AF.
Background: Disturbances in atrial microcirculation is recognized as a risk factor for atrial fibrillation (AF). Aim: The aim of this study was to determine the associations between circulating soluble vascular cell adhesion molecule-1 (sVCAM-1) and the risk of AF and a one-year prognosis among consecutive inpatients. Methods: Eighty consecutive inpatients hospitalized due to non-valvular AF and 80 consecutive inpatients admitted for exacerbation of chronic coronary syndrome (control group) were enrolled in the study. A cardiologic workup was performed and blood sVCAM-1 concentration was determined using the ELISA method. Results: Patients with AF had similar blood sVCAM-1 concentration compared to the control group. AF patients treated with new oral anticoagulants (NOACs) were significantly less likely to have a sVCAM-1 concentration elevated above the median value than patients treated with warfarin (34.2% vs 65.8%; p = 0.01). Patients with an increased percentage of fat mass (FM) had lower sVCAM-1 concentration. The risk of all-cause mortality and MACE during follow-up rose in individuals with elevated sVCAM-1 (≥ 1242 and ≥ 587 ng/ml, respectively) with (OR; 95%CI): 5.39; 1.57-18.45; p = 0.007, and 6.00; 1.18-30.37; p = 0.03, respectively. Risk of death rose with increase in the ratio of sVCAM-1 and FM (1.02; 1.00-1.04; p = 0.019). Conclusions: Elevated sVCAM-1 was associated with all-cause mortality and MACE during one-year follow- up, but do not links the risk of AF. Use of NOACs may favorable affect endothelial function, A lower level of sVCAM-1 in obese patients may mediate the phenomenon of the “obesity paradox” in patients with AF.
No takes yet. Share an insight, caveat, or question.
Anaszewicz et al. (2020) conducted a cohort in Non-valvular atrial fibrillation (n=160). Elevated sVCAM-1 concentration vs. Lower sVCAM-1 concentration was evaluated on All-cause mortality (OR 5.39, 95% CI 1.57-18.45, p=0.007). Elevated sVCAM-1 concentration (≥ 1242 ng/ml) was associated with a significantly increased risk of all-cause mortality (OR 5.39) during a one-year follow-up.
Synapse has enriched 5 closely related papers on similar clinical questions. Consider them for comparative context: